Trial · NCT05006573
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | exacerbations per year | LEAST_SQUARES_MEAN |
| SECONDARY | Time to First Exacerbation in the Double-blind Treatment Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | days | MEDIAN |
| SECONDARY | Change From Baseline in QoL-B-RSS Over the Double-blind Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Pre-dose Pre-BD FEV1 Over the Double-blind Treatment Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | L | MEAN |
| SECONDARY | Change From Baseline in LCQ Total Score Over the Double-blind Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Physical Functioning Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Role Functioning Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Emotional Functioning Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Social Functioning Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Vitality Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Health Perceptions Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Treatment Burden Scale | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in SGRQ Total Score Over the Double-blind Treatment Period | through Double-blind period, at least 28 weeks and up to 52 weeks | Full Analysis Set: All patients randomized and receiving at least one (1) dose of Investigational Product are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05006573/outcomes